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1Chapter
Understanding the Mechanisms of 
Pain in Rheumatoid Arthritis
Kathryn Biddle and Nidhi Sofat
Abstract
Pain is a debilitating feature of rheumatoid arthritis (RA) and is often described 
by patients as their most important symptom. Rheumatoid arthritis pain has 
traditionally been attributed solely to joint inflammation, however despite the 
advent of increasingly effective disease modifying agents, patients continue to 
report pain at long term follow up. The cause for ongoing pain is multifactorial and 
includes joint damage and pain sensitisation. In this book chapter, we will describe 
the mechanisms underlying the distinct components of pain which are manifest in 
rheumatoid arthritis and discuss why a thorough assessment of pain is vital to target 
treatments appropriately.
Keywords: pain, rheumatoid arthritis, inflammation, pain sensitisation, nociceptors, 
rheumatology
1. Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory disease with a preva-
lence of between 0.5 to 1% in different worldwide populations [1]. Inflammation 
predominantly affects the joints causing synovitis, pannus formation and if left 
untreated, joint destruction. Patients with RA classically present with tender and 
swollen joints, early morning joint stiffness and systemic symptoms such as fatigue. 
Severe pain is a particularly debilitating feature of RA that is commonly described 
as patients’ most important symptom [2]. In addition to causing a significant impact 
on quality of life, studies have shown that RA pain is associated with psychological 
distress, impaired physical and social function and increased healthcare costs [3].
The pathogenesis of pain in RA is multifactorial. Traditionally, pain was entirely 
attributed to synovitis and consequent joint destruction. With the advent of 
increasingly effective disease modifying agents, joint inflammation has become 
a more treatable cause of pain and joint destruction is preventable. Indeed, the 
randomised controlled trials (RCTs) that supported the use of classical disease 
modifying anti-rheumatic drugs (DMARDs), showed statistically and clinically 
significant reduction in pain with treatment [4]. However, despite effective control 
of inflammation and disease remission, patients have continued to report trouble-
some pain at follow-up [5]. The same has been shown in patients taking biologic 
DMARDs [6]. This suggests that pain does not always fully resolve with the effec-
tive suppression of synovitis [7]. Observational studies have also highlighted the 
complex relationship between pain and inflammation in patients with RA. For 
example, large discrepancies between objective measures of inflammation such as 
acute-phase proteins and reported pain, have been shown in some patients with RA 
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[8]. Taken together, this evidence suggests that inflammation and joint destruc-
tion alone cannot account for the total pain manifesting in RA. Indeed, increasing 
evidence supports a role for aberrant pain processing, including peripheral and 
central pain sensitisation, in the pathogenesis of pain in RA. Throughout this book 
chapter, we will explore the different mechanisms underlying the perception of 
pain in patients with RA.
2. Inflammation in RA
RA is a pathologically heterogenous autoimmune condition. The disease can 
broadly be divided into sero-positive and sero-negative subtypes. In sero-positive 
patients, the presence of anti-citrullinated peptide antibodies (ACPAs), is associ-
ated with more severe joint damage and increased mortality [9]. In these patients, 
ACPAs bind to citrullinated autoantigens including fibrinogen, vimentin, collagen 
type 4 and α-enolase, resulting in the formation of immune complexes (ICs) [10]. 
ICs activate the complement system and trigger inflammatory cell infiltration 
within the synovium [11].
The pathology of RA is characterised by the activation of cells of both the innate 
and adaptive immune system within the synovial matrix. The innate immune 
response consists of macrophages, mast cells and dendritic cells. These cells pro-
duce inflammatory mediators including cytokines, chemokines, lipids, proteases 
and growth factors. These mediators attract neutrophils and activate cells of the 
adaptive immune system, such as T cells, B cells and plasma cells. The inflamma-
tory cytokines produced during the innate immune response shape the subsequent 
activation of the adaptive immune system. For example, cytokines produced in the 
early phases of inflammation regulate the differentiation of naïve T helper cells into 
T helper cell subsets and the subsequent T cell response.
In RA, the inflammatory milieu within the synovium is characterised by com-
plex cytokine and chemokine interactions. Cytokines including TNF-α and IL-6 
appear to be particularly important, and biologic agents targeting these mediators 
are well-established treatments for RA [12].
Inflammation results in a catabolic state within the joint. One of the pathog-
nomonic features of RA is the synovial pannus, a hypertrophied area of synovium 
with tissue destructive properties [13]. Within the pannus, synovial fibroblasts 
assume an inflammatory phenotype resulting in enhanced cartilage catabolism 
and synovial osteoclastogenesis [14]. Cytokine-mediated chondrocyte activation 
results in the stimulation of catabolic pathways. Enzymes including matrix metal-
loproteinases (MMPs) are activated to degrade the cartilage matrix [15]. Bone 
erosion is stimulated by the interaction between RANK-L on fibroblasts, T and B 
cells and its receptor RANK on dendritic cells, macrophages and pre-osteoclasts 
[16]. Ultimately, this process can result in cartilage and bone destruction and joint 
deformity.
Therapies that target inflammation such as conventional DMARDs and biologic 
therapies are effective at suppressing synovitis and reducing joint destruction. The 
treat-to-target approach is widely recommended for the management of RA. This 
strategy involves regular monitoring of disease activity, using validated scoring 
measures such as the DAS28, and escalation of treatment if a target is not reached. 
RCTs have found that this approach substantially improves disease activity, 
radiographic progression, quality of life and physical function [17]. These immu-
nomodulatory agents have been shown to reduce pain, albeit not completely [18]. 
Throughout the next section of this chapter, we will discuss the inflammatory basis 
of pain in RA.
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2.1 Pain and joint inflammation
Inflammation has long been accepted to cause pain. Indeed, pain was one of 
the cardinal features of inflammation, as defined by Celsus in the first century 
[19]. Pain secondary to inflammation can be classified into acute or chronic pain. 
The neurotransmission of acute pain signals in response to noxious stimulation 
involves the activation of a specialised subset of sensory neurons called nocicep-
tors. Nociceptors innervate peripheral tissues, including joints, and transmit 
painful stimuli to the dorsal root ganglion (DRG). There are many subsets of 
nociceptors, each responding to different types of noxious stimuli. Aδ and C 
fibres are the two main types of primary afferent nociceptors [20]. Whilst both 
Aδ and C fibres are found in superficial organs, such as the skin, C-fibres gener-
ally supply deeper structures such as joints [20]. C-fibres are activated by ther-
mal, chemical or mechanical stimulation, resulting in poorly localised, dull pain 
sensation [20].
The activation of nociceptors involves the stimulation of ligand-gated and 
voltage-gated ion channels including transient receptor potential cation channel, 
subfamily A, member 1 (TRPV1), transient receptor potential cation channel, 
subfamily A, member 1 (TRPA1), Nav1.7, Nav1.8, and Nav1.9 channels, which are 
expressed on peripheral nerve terminals [21]. Activation of these channels results 
in the stimulation of intracellular signalling pathways and the transmission of acute 
pain signals [21]. In the longer term, chronic inflammation results in long lasting 
changes in nociceptor signalling resulting in peripheral pain sensitisation, a phe-
nomenon that we will discuss later in this chapter.
2.2 Synovial joint structures and pain
Arthritic pain is thought to be mediated by nociceptors that innervate the 
synovium and subchondral bone. In contrast, under physiological conditions, 
cartilage is an aneural and avascular tissue. This is illustrated in Figure 1.
In RA, chronic inflammation is thought to result in structural and functional 
changes in the peripheral innervation of joints. This has been shown in animal 
Figure 1. 
Diagram of a synovial joint. A synovial joint consists of two articulating cartilage surfaces surrounded by a 
synovial membrane. Synovial fluid fills the synovium. Under physiological conditions, cartilage is avascular 
and aneural. Nociceptors innervating the synovium and subchondral bone are responsible for arthritic pain. In 
contrast, stretch receptors, innervating the fibrous capsule are responsible for proprioception.
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models where chronic synovitis results in increased innervation of the synovium 
and increased spontaneous and mechanical-induced firing of articular primary 
afferents [22, 23].
2.3 Nociceptor pathways
Nociceptor pathways mediating acute pain perception in response to inflammation 
are well defined. In the periphery, local immune cells release inflammatory mediators, 
such as cytokines, that act on the peripheral nerve terminals of nociceptor neurons. 
This activates the nociceptors to transmit signals via the DRG through the spinotha-
lamic tract to the higher cortical centres, resulting in the perception of pain. It is also 
well accepted that inflammation can result in heightened nociceptor sensitivity to both 
noxious and innocuous stimuli. In this case, the activation of nociceptors by inflam-
matory mediators triggers intracellular signalling cascades that reduce the threshold 
for nociceptor neurons to fire action potentials [21]. This results in heightened pain 
sensitivity which can manifest as allodynia; the sensation of pain arising from a 
non-painful stimulus, or hyperalgesia; a heightened sensation of pain in response to 
painful stimulation. Throughout the next section of this chapter, we will discuss the 
inflammatory mediators that stimulate nociceptor activation and sensitisation in RA.
2.4 Pain and innate immunity
Cells of the innate immune system, including neutrophils, mast cells and macro-
phages, release noxious inflammatory mediators and have been shown to stimulate 
pain and pain sensitisation in a wide range of models and systems. For example, in 
mouse models of carrageenan-induced inflammatory pain, neutrophils migrate to 
tissues and sustain pain through the production of cytokines and prostaglandin E2 
[24]. In incisional wound injury, macrophages (CD11b + myeloid cells) have been 
shown to mediate acute pain and pain sensitisation [25]. Mast cell degranulation 
activates nociceptor firing acutely and may also contribute to pathology of chronic 
pain and mast cells have been shown accumulate in chronic inflammatory condi-
tions such as complex regional pain syndrome [26, 27]. Throughout the next part of 
the chapter, we will discuss the noxious inflammatory mediators that are released 
by innate immune cells.
2.5 Lipid mediators of pain
Pro-inflammatory lipids include cyclooxygenase (COX) dependent molecules 
such as prostanoids (prostaglandins, prostacyclins and thromboxanes). COX-
dependent molecules are well known to cause pain and pain sensitisation and inhi-
bition of the COX enzyme, using non-steroidal anti-inflammatory drugs (NSAIDs), 
is used for the suppression of pain and inflammation. Indeed, NSAIDs are potent 
analgesic and anti-inflammatory medications which are effective for the treatment 
of acute inflammatory pain including synovitis [28].
Studies have investigated the mechanism of action underlying the noxious effect 
of prostaglandins. Prostaglandin E2 (PGE2) has been shown to activate nociceptors 
through the binding of EP1-EP4 receptors. This stimulates pain and pain sensitisa-
tion via multiple mechanisms. PGE2 stimulates proximal ion channels in nocicep-
tive neurons. This sensitises the neurons to painful stimuli [29]. PGE2 activates 
more persistent pain sensitisation via PKA and PKC-mediated activation of NFκB in 
the dorsal root ganglion neurons [30].
Many other classes of pro-inflammatory lipids are thought to be involved in 
the activation of nociceptor activity. For example, lysophosphatidic acid and 
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sphingosine-1-phosphate are produced during inflammation and have been shown 
to activate nociceptors leading to increased TRPV1 activity [31]. Leukotrienes may 
also have an noxious effect and the injection of leukotriene B4 has been shown to 
activate C and Aδ-fibres in rat models and induce hyperalgesia in humans [21, 32].
More recent work has also demonstrated a role for anti-inflammatory and pro-
resolving lipids in the silencing of pain. For example, pro-resolving lipids, including 
lipoxins, resolvins and protectins have generally been shown to have analgesic 
effects [33]. Further work is required to characterise the underlying molecular 
pathways but these mediators may represent targets for the future treatment of 
pain [33].
2.6 Neurotransmitters and pain
Innate immune cells release neurotransmitters capable of modulating pain trans-
mission. For example, mast cells contain histamine and serotonin that are released 
on degranulation. Histamine triggers pain sensitisation through the activation of H1 
and H2 receptors expressed on nociceptors [34]. This results in increased expression 
of Nav1.8 channels and increased sensitivity to noxious stimuli [34, 35].
2.7 Cytokines and pain
Inflammatory cytokines represent another important class of molecules that 
stimulate nociceptors and activate pain sensitisation. IL-1β was the first cytokine 
to be described as hyperalgesic [36]. This finding was seminal in the field of neuro-
immunology and represented early evidence for the cross-talk between the immune 
system and pain sensitisation. Cytokines have now been found to play important 
roles in pain modulation in most painful conditions, including RA. Notably, pro-
inflammatory cytokines including IL-1β, IL-6, TNF-α, IL-17A and IL-5, have all 
been shown to active nociceptors directly [21].
IL-1β sensitises nociceptors through different intra-cellular signalling pathways. 
Firstly, IL-1β activates the p38 MAPK-mediated phosphorylation of Nav1.8 sodium 
channels resulting in increased action potential generation and an associated 
mechanical and thermal hyperalgesia [37]. Secondly, the activation of IL-1R1 by 
IL1-β, has also been shown to result in increased TRPV1 expression on nociceptors, 
resulting in thermal pain sensitisation in animal models [38].
IL-6 stimulates pain sensitisation directly and indirectly. Directly, IL-6 activates 
nociceptors via the signal transducer gp 130 leading to increased TRPV1 and TRPA1 
expression [39]. Indirectly, IL-6 activates nociceptors via the production of prosta-
glandins [39]. TNF-α also induces pain sensitisation via TRPA1 and TRPV1, how-
ever TNF-α mediated inflammatory pain appears to be dependent on prostaglandins 
[40]. Indeed, COX-2 inhibitors have been shown to inhibit TNF-α induced capsaicin 
responsiveness in cultured nociceptors [41]. TNF-α also modulates nociceptor sen-
sitivity through the activation of p38 MAPK mediated phosphorylation of Nav.18 
and Nav1.9 sodium channels [42].
Increasing work suggests a role for IL-17 in pain sensitisation. Indeed, many 
painful autoimmune diseases, such as RA and psoriasis, are characterised by a Th17 
immune response. IL-17A has been shown to be broadly expressed by nociceptors 
and IL-17 has been demonstrated to induce a rapid increase in neuronal excitability 
[43]. In animal models of RA, IL-17 has been shown to induce hyperalgesia, through 
a mechanism dependent on the amplification of TNF-α, IL-1B, CXCL-1, endothelin 
1 and prostaglandins [44].
In summary, IL-1β, IL-6, TNF-α and IL-17 stimulate pain and pain sensitisation 
through the synthesis of prostaglandins and/or the activation of sodium or TRP 
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Figure 2. 
Inflammatory mediators and pain. Figure 2 Summarises the inflammatory mediators that have been shown 
to activate and sensitise nociceptors21. As illustrated, innate and adaptive immune cells release inflammatory 
mediators that act on their respective receptors to activate nociceptors and sensitise pain signalling through Nav 
and TRP channels.
channels. The different cytokines appear to act via different intracellular signalling 
pathways, however it remains unclear whether different immune responses (e.g. 
Th1, Th2 or Th17) induce different pain characteristics through the activation of 
specific nociceptors and pain receptors.
2.8 Immune derived growth factors in pain
Innervation by nociceptors is a dynamic process affected by neurotrophic 
factors. These factors are often upregulated in response to inflammation or tissue 
injury and are important to restore the density of innervation post-injury [21]. 
If there is inappropriate or excessive release of neurotrophic factors, heightened 
pain sensitivity can occur [21]. Nerve growth factor (NGF) is an important 
neurotrophic factor that is secreted by innate immune cells during the acute 
phase of inflammation. NGF activates the receptor TrkA on nociceptors, stimu-
lating the P13K/Src kinase pathway and the phosphorylation of TRPV1 and its 
translocation into the cell membrane [45]. This results in the rapid sensitisation 
of nociceptors in response to stimulation by NGF. In the longer term, NGF has 
been shown to stimulate axonal terminal sprouting, contributing to increased 
pain sensitivity [46].
2.9 A role for ACPAs in pain in RA
It is well established that arthralgia can precede overt joint inflammation and 
that joint pain is often one of the first symptoms of emerging RA. The mechanism 
underlying arthralgia preceding inflammation remains unclear but a role for ACPAs 
has been suggested. Observational studies have shown that ACPAs frequently 
occur in the preclinical phase of disease and can be detected months to years prior 
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to diagnosis [47]. Experimental studies have raised the possibility that ACPAs 
can induce pain via a pathway independent of joint inflammation. In one study, 
mice injected with human or murine ACPAs developed increased pain sensitivity, 
despite no signs of joint inflammation. In this study, ACPAs were shown to bind 
to osteoclasts in the bone marrow, and induce CXCL1/2 expression and release. 
Intra-articular injection of CXCL1/2 was shown to evoke pain-like behaviour and 
this was inhibited by an IL-8 inhibitor, reparixin [48]. Further work is required to 
confirm this hypothesis. If correct, it could alter the management of ACPA positive 
arthralgia and offer new therapeutic targets in the management of early RA.
In summary, inflammation is a well-accepted cause of pain in RA and many 
inflammatory mediators have been shown to stimulate nociceptor activation and 
sensitisation, as summarised in Figure 2.
Despite the important role for inflammation in pain in RA, the extent of 
inflammation does not always correlate with the severity of total pain reported 
RA patients. Indeed, observational studies have shown that changes in inflamma-
tion account for only 40% of changes in pain in RA patients [49]. Furthermore, 
factors associated with the degree of inflammation such as serology, acute phase 
response and joint damage correlate poorly with pain prognosis in RA patients [7]. 
Moreover, in common with other chronic pain conditions, psychosocial factors 
and female gender predict pain prognosis more accurately than the severity of 
inflammation [7]. Therefore, additional mechanisms must be responsible for the 
pain experienced in RA. These mechanisms include joint damage and aberrant pain 
sensitisation.
3. Joint damage and pain
The contribution of structural joint changes to the total pain in RA is contro-
versial. In patients with advanced RA, erosions and joint space narrowing are 
associated with disability and make a small but significant contribution to total 
reported pain [50]. Moreover, patients with advanced disease show an improve-
ment in pain following joint replacement surgery [51]. However, as more effective 
disease modifying protocols have been developed, structural joint damage in 
RA has decreased and corresponding rates of orthopaedic surgery have declined 
[52]. The prevention of joint damage has produced superior pain outcomes but 
it is not clear how much of this can be attributed to the prevention of structural 
damage versus the suppression of inflammation or prevention of pain sensitisa-
tion. In recent studies, radiographically assessed joint damage appears to make a 
small contribution to pain in RA patients [53]. However, some of this pain may 
be explained by coincident osteoarthritis (OA), which occurs in a similar demo-
graphic of patients.
The correlation between joint damage and pain severity appears weak, although 
investigation on this subject has primarily occurred in patients with OA and 
relatively little data exists for patients with RA. In OA, structural joint changes do 
not correlate well with joint pain [54]. The severity of radiographic OA has been 
shown to explain <20% of the variance in pain intensity [54]. Furthermore, post-
joint replacement, many patients continue to report pain. 10% of patients post-
total hip replacement (THR) and 20% post-total knee replacement (TKR) report 
unfavourable long term pain outcomes [55]. This suggests that structural joint 
damage alone cannot explain the total pain experienced in OA. Like in RA, central 
pain sensitisation has been proposed to explain the pain not accounted for by joint 
destruction [56].
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4. Central pain sensitisation and RA
Processing by the central nervous system (CNS) can affect pain reporting, sen-
sitivity, intensity and pain characteristics [57]. Aberrant pain processing can result 
in central pain sensitisation; an amplified response of the central nervous system to 
peripheral nociceptive input [58]. The term central sensitisation was coined in 1989 
by Woolf and colleagues based on work in the rat model showing hyperexcitability 
of spinal cord neurons in response to peripheral tissue injury [58]. Physiologically, 
central sensitisation represents a state of hyperexcitability of spinal and supra-
spinal structures due to amplified neuronal signalling involving enhanced synaptic 
and neurotransmitter activities [59].
An increasing abundance of evidence supports the role for central pain sensitisa-
tion in RA and an understanding of central sensitisation is important to optimise 
patient treatment. Clinically, pain secondary to an inflammatory flare must be 
differentiated from pain secondary to central sensitisation as they require vastly 
different management approaches. Throughout the next part of this chapter, we 
will discuss the molecular basis of pain transmission from the periphery to the CNS, 
clinical evidence supporting a role for pain sensitisation in RA and some proposed 
mechanisms for pain sensitisation in the DRG and in the cerebral cortex.
4.1 Molecular basis of pain sensitisation
As discussed previously, A-δ and C nociceptive neurons are activated by inflam-
matory mediators in the periphery. These fibres converge at the DRG, along with 
non-noxious A-β fibres. Following activation, nociceptor fibres release substance P 
(SP), calcitonin gene-related peptide (CGRP), glutamate, aspartate and NGF at the 
afferent nerve endings into the synaptic cleft [60]. These neurotransmitters activate 
their corresponding receptors on post-synaptic neurons. Activation of post-
synaptic receptors results in intracellular signalling changes. For example, activa-
tion of NMDA receptors results in increased membrane permeability, intracellular 
entry of calcium, activation of protein kinases and the expression of c-fos [61]. 
These signalling changes result in the hyperexcitability of the secondary neurons 
and amplification of the peripheral noxious stimulus. Post-synaptic neurons ascend 
in the spinothalamic tract to the thalamus, hypothalamus, limbic system and the 
somatosensory cortex [61]. These signalling pathways are summarised in Figure 3.
Animal models of RA have been used to investigate the molecular mechanisms 
underlying spinal pain sensitisation. In these models, molecular changes have 
been shown to occur in the DRG, spinal neurons and spinoreticular neurons. For 
example, in complete Freund’s adjuvant (CFA) induced arthritis models, increased 
expression of SP, CGRP, NPY, c-fos, TRPV1, P2X3 and Trk-A receptors in the DRG 
have been demonstrated [62]. These changes are thought to result in hyperexcitabil-
ity of spinal neurons and enhanced sensitivity to nociceptor signalling.
4.2 Clinical evidence for a role of pain sensitisation in RA
Patients with RA show widespread reductions in pain threshold and increased 
pain sensitivity, not only over inflamed joints but at distant, non-articular sites 
[62]. Evidence to support this has come from clinical studies using techniques 
such as quantitative sensory testing (QST). This technique involves the applica-
tion of stimuli under standardised testing protocols and the quantification of the 
participants sensory experience. QST employs different tools for the assessment 
of the perception of vibration, touch, proprioception, pinprick or blunt pressure 
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sensitivity. RA patients have a lower pain threshold than healthy controls with QST 
[63]. Furthermore, sensitisation has been shown to affect a wide range of sensory 
modalities, including thermal and mechanical stimulation.
Studies have demonstrated that pain thresholds vary substantially between 
patients with RA. Multiple factors have been shown to correlate with differences in 
pain threshold. Importantly, these include high tender joint count and prolonged 
disease duration [64]. This suggests that the persistence of nociceptive stimulation 
results in long-term changes in pain processing resulting in central pain sensitisa-
tion. Other factors that have been shown to influence pain threshold include sleep 
quality, psychosocial factors and analgesic use [65].
Repetitive sensory stimulation, also known as temporal summation, is another 
experimental model that has been used to investigate central sensitisation in RA. 
Temporal summation occurs when the time between stimuli is short enough to 
prevent the dissipation of postsynaptic action potentials before re-activation [66]. 
This results in a higher membrane potential, increasing the probability that further 
stimulation will result in post-synaptic activation. In healthy controls, repetitive 
stimulation results in the reduction of pressure pain thresholds [62]. Studies have 
shown that this response is augmented in RA patients [67]. This has also been 
demonstrated electrophysiologically through the measurement of action potentials 
in response to repetitive stimulation. In healthy controls, there is an increase in the 
amplitude of action potential evoked from repetitive stimulation using noxious 
stimulation. This response is amplified in RA patients and has been shown to cor-
relate with disease activity scores and high tender joint counts [68].
4.3 Neuropathic pain in RA
In addition to measuring pain thresholds, pain characteristics can be analysed 
to assess the possible contribution of pain sensitisation to overall pain experi-
ence. Specifically, pain questionnaires are commonly used to detect the presence 
of neuropathic-sounding pain. Neuropathic pain is the perception of pain in the 
absence of nociceptive input or peripheral tissue damage and is caused by pathology 
Figure 3. 
A simplified diagram of pain signalling pathways. As illustrated, noxious stimulation activates A-δ and C 
fibres in the periphery. These fibres converge at the DRG and activate post-synaptic neurons that ascend to 
higher cortical centres via the spinothalamic tract.
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of the peripheral or central nerves. A classic example of neuropathic pain is sciatica. 
This pain has distinct characteristics such as burning, radiation, shooting, tingling 
and sensitivity to non-painful stimuli (i.e. allodynia). RA can be associated with 
neuropathic pain through several mechanisms including compression neuropathy 
(e.g. carpal tunnel syndrome), co-morbidities (e.g. diabetes), vasculitis (result-
ing in mononeuritis multiplex) or drug therapies (e.g. gold or leflunomide). 
Nevertheless, emerging evidence suggests that RA itself can result in neuropathic 
pain through the induction of aberrant pain processing.
The painDETECT questionnaire enables the classification of pain into likely, 
possibly or unlikely to be of neuropathic origin. Patients with RA often describe 
pain with neuropathic features and painDETECT questionnaires can yield between 
5 to 20% fulfilling criteria for “likely neuropathic pain” [62]. A significant propor-
tion of these patients have no underlying evidence of neuropathy. One study dem-
onstrated that only 33% of RA patients fulfilling clinical criteria for neuropathic 
pain had clinical evidence of neuropathy [69]. Of the remaining patients, 57% were 
shown to have subclinical or axonal neuropathy [70]. This left a significant number 
of patients with RA who reported neuropathic-sounding pain in the absence of 
objective nerve injury. It has been suggested that this pain occurs secondary to 
pain sensitisation however, this has not been proven. Nevertheless, neuropathic-
sounding pain is an important clinical feature as it predicts inferior pain outcomes. 
Indeed, a positive correlation between VAS pain scores and painDETECT scores has 
been demonstrated and patients with probable or likely neuropathic pain have been 
shown to report significantly higher VAS scores than patients without neuropathic-
sounding pain [71].
Although the painDETECT questionnaire is a useful tool for characterising pain, 
care must be taken to interpret results based only on questionnaires. Furthermore, 
confounding effects with pain severity may affect interpretation. Patients with 
fibromyalgia demonstrate high painDETECT scores, although evidence of pathol-
ogy in the peripheral or central nervous system has been difficult to demonstrate. 
This raises the question of whether painDETECT scores identify pain with similar 
features to neuropathic pain rather than neuronal pathology itself. Further work is 
required to fully understand the significance of neuropathic sounding pain in RA.
4.4 Fibromyalgia-RA
The association between fibromyalgia and RA sheds light on the complex rela-
tionship between inflammation, pain and central pain sensitisation. Fibromyalgia 
(FM) is the prototypical central pain sensitivity syndrome. Clinically, FM is char-
acterised by chronic widespread pain, sleep disturbance and impaired cognition 
[72]. Observational studies have shown that the prevalence of fibromyalgia in RA 
patients is much higher than in the general population with estimated prevalence of 
18-24%, compared to 2-4% in non-RA cohorts [73, 74].
Two groups of fibromyalgia (FM) have been characterised. Patients with “pri-
mary” FM report pain in the absence of identifiable nociceptive input [72]. These 
patients generally report regional pain syndromes that progress to widespread pain 
phenotypes with time. “Secondary” FM occurs when aberrant centralised pain 
processing occurs in the context of identifiable nociceptive input, for example in 
inflammatory arthritis [72]. It is not yet clear whether these conditions represent 
the same or different diseases.
The co-existence of FM in RA patients is associated with increased pain scores, 
a poorer quality of life and worse patient-reported outcomes. In a meta-analysis of 
18 studies, RA patients with co-morbid FM had significantly higher pooled DAS28 
scores than those without FM [73]. When studies reported individual components 
11
Understanding the Mechanisms of Pain in Rheumatoid Arthritis
DOI: http://dx.doi.org/10.5772/intechopen.93829
of the DAS28, patients with co-existent FM had significantly higher tender joint 
counts and higher patient global assessment scores than those without FM [73]. 
Objective measurements including swollen joints and inflammatory markers were 
not significantly different between RA patients with and without FM [73]. Other 
scoring systems including the simplified disease activity index (SDAI) and the clini-
cal disease activity index (CDAI) were also higher in RA patients with comorbid FM 
[75]. A large study of 11,866 RA patients reported that those with comorbid FM had 
increased pain, poorer quality of life and greater functional limitation [76].
The recognition of FM in RA patients is important for multiple reasons. Firstly, 
both RA and FM commonly present with pain and fatigue. Differentiation of 
the conditions and diagnosis of co-morbidity is vital for patient management as 
different treatment approaches are required. In FM-RA patients, characterisa-
tion of the pain is imperative to manage patients appropriately. For example, 
inflammatory flares must be differentiated from painful flares secondary to FM. 
Secondly; recognition of patients with secondary FM offers an important insight 
into the pathogenesis of pain centralisation which is currently poorly understood. 
Nevertheless, caution should be used when interpreting the association between 
inflammatory arthritis and FM as the FM diagnostic tools have not been validated 
in RA. Furthermore, confounding factors including female sex and mental health 
problems are more prevalent in both FM and RA.
4.5 Central mechanisms of pain sensitisation
Central pain sensitisation is thought to occur at both spinal and supraspinal 
levels [62]. At the level of the DRG, spinal hyperexcitability occurs secondary 
to ongoing nociceptive input and pain transmission can be modified by inhibi-
tory or facilitating neurones that can be modulated by descending signals from 
supraspinal levels [72]. Spinal pain facilitation is thought to be responsible for the 
spread of mechanical allodynia beyond the innervated field of cutaneous neurons. 
This has been shown in models using the intradermal injection of capsaicin [77]. 
Both ipsilateral and contralateral pain facilitation is thought to occur second-
ary to chronic inflammation and in RA patients, enhanced responses to noxious 
stimulation occurs at sites distal from inflamed joints [78]. Pain sensitisation is 
also thought to occur at supraspinal levels and brain imaging has demonstrated 
changes in cerebral activation secondary to chronic pain. Throughout the next 
section of the chapter, we will discuss the evidence of supraspinal pain sensitisa-
tion in RA.
4.6 Brain neuroimaging and pain
Imaging studies have attempted to characterise the neuronal circuitry resulting 
in cerebral sensitisation in RA. Structural MRI studies have shown increased grey 
matter density in the basal ganglia of RA patients compared to controls. This area 
is involved in both motor function and in pain processing [79]. Functional imaging 
has been used to investigate neuronal activation in response to pain. Functional 
MRI (fMRI) studies have demonstrated differences in resting state functional 
connectivity between RA patients and controls. In RA patients, there is increased 
connectivity between frontal midline regions that are implicated in pain processing, 
including the supplementary motor area and the mid-cingulate cortex, to senso-
rimotor regions [80]. Moreover, in RA patients, increased EEG activity has been 
reported in response to repetitive painful stimuli [81]. These studies suggest that 
aberrant pain cerebral pain processing may occur in RA and therefore, may result in 
augmented pain responses.
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A further level of complexity is introduced when the biopsychosocial model of 
pain is considered. This suggests that cognitive and emotional processes are also 
critical contributors to the overall perception of pain. Indeed, the transmission of 
nociceptive information is influenced by multiple higher-level factors, such as mood, 
attention and cognitive factors, to form the resulting pain experience [82]. Mood is 
a particularly important cognitive factor in RA and meta-analysis has revealed that 
16.8% of patients with RA meet the criteria for a major depressive episode [83].
In RA patients, depressive symptoms have been found to correlate significantly 
with tender joint count [84]. The medial prefrontal cortex has been suggested to 
play an important role in mediating the relationship between pain severity and 
depressive symptoms. Evidence has demonstrated an association between depres-
sive scores (measured using the Becks depression index), tender joint count and 
MPFC activation during provoked joint pain. In the same study, MPFC activation 
co-varied significantly with limbic activation, an area involved in affective process-
ing. This led the authors to suggest that the MPFC engages areas important for 
self-relevant processing to mediate the relationship between pain and affective 
symptoms [84]. In summary, pain processing by higher brain centres affects pain 
perception and the affective response to pain in RA. Although we are beginning 
to shed light on higher processing using functional imaging studies, more work is 
required to fully appreciate the complexities of central pain processing in RA.
5. Management of pain in RA
The cornerstone of RA treatment is the suppression of inflammation using the 
treat to target approach. However, disease remission will not lead to the complete 
resolution of pain in all patients and a multi-modal approach to pain manage-
ment is very important. This approach has been recommended by rheumatology 
associations. For example, EULAR have recommended a patient centred approach 
to pain management where a biopsychosocial framework should be adopted [85]. 
Specifically, clinicians should differentiate between local and generalised pain and 
should be guided by patient needs, preferences, pain characteristics, inflamma-
tion and psychological factors. Treatments should include education, psychical 
therapies, orthotics, psychosocial interventions, sleep hygiene, pharmacological 
and joint-specific treatment options. Throughout this section of the review, we will 
discuss the different facets of pain management.
5.1 Pharmacological therapies
Pharmacological treatments include analgesic agents and immunomodula-
tory medications. Many analgesic agents are used in the management of RA pain 
although their use is rarely supported by high-quality RCTs [62]. Commonly 
used analgesic medications include paracetamol, NSAIDs, opioids and tricyclic 
anti-depressants. Optimal pain management should involve the characterisation 
of pain phenotype, in particular, differentiation of peripheral and central pain 
mechanisms. Pain phenotype could alter the choice of analgesic agent. For example, 
NSAIDs have been shown to reduce inflammatory pain in RA but not central pain in 
FM [86]. More work is required to define optimal analgesic use in different subsets 
of RA patients.
The cornerstone of RA management is the suppression of inflammation. 
Medications that reduce synovial inflammation are well known to reduce pain in 
RA patients. Immunomodulatory medications used in RA include glucocorticoids, 
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conventional synthetic DMARDs and biologic DMARDs. Glucocorticoids are 
commonly used to treat acute inflammatory flares and have been shown to provide 
significant pain relief [87]. Extensive evidence supports the efficacy of traditional 
DMARDs, including methotrexate, sulfasalazine and leflunomide, in reducing joint 
pain. The analgesic effect of cDMARDs parallels the suppression over a time course 
of weeks to months [62]. Combination therapy has been shown to be superior than 
monotherapy and the addition of a biologic agent has been shown to reduce pain 
even further [88, 89]. Nevertheless, pain improvement may plateau despite effective 
suppression of inflammation and studies have shown that this plateau is worse that 
the UK mean [7]. Persisting pain may result from centrally mediated pain hyper-
sensitivity and may respond better to neuropathic agents or non-pharmacological 
treatments including education, exercise and cognitive behavioural therapy (CBT) 
than those treatments focusing on management on nociceptive triggers alone.
5.2 Neuropathic agents
Neuromodulatory medications used for the treatment of neuropathic pain 
include antidepressants such as tricyclic antidepressants (e.g. amitriptyline) and 
serotonin-noradrenaline re-uptake inhibitors (e.g. duloxetine) or anti-convulsants, 
e.g., pregabalin or gabapentin [90]. The clinical efficacy of these medications well 
well-established in conditions including neuropathic pain and generalised pain 
sensitisation syndromes such as fibromyalgia [91, 92]. Neuropathic agents are 
sometimes used for the treatment of pain in RA however evidence from high quality 
RCTs is lacking [93]. However, in other localised pain conditions such as hand OA, 
pregabalin has been shown to improve pain and function [94]. Further work is 
required to establish the role for neuropathic medications in RA patients.
5.3 Psychosocial therapies
Psychological pain management programmes, including cognitive behavioural 
approaches and mindfulness, have an important role in the management of chronic 
pain. An abundance of evidence supports the efficacy of psychosocial approaches to 
pain management in chronic pain conditions [95]. In RA, CBT has the best evidence 
base for the management of pain with multiple meta-analyses confirming efficacy 
[96, 97]. In addition to benefiting pain symptoms, CBT has been shown to improve 
other symptoms including fatigue in RA patients [98]. Psychosocial therapy may 
be most efficacious when offered early in the disease course however further work 
is required to determine which subset of patients should be offered psychosocial 
therapies and at which time-point in their illness [99].
5.4 Exercise based therapies
Exercise based therapies have an important role in the management of RA. 
Evidence has shown that resistance exercises decrease disability and functional 
impairment [100]. Furthermore, a meta-analysis of five studies revealed that resis-
tance exercises resulted in a trend towards a small positive effect on VAS pain [100].
6. Conclusion
In conclusion, pain remains a significant problem for many patients with RA 
and is associated with psychological distress, fatigue and reduced quality of life. 
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In RA patients, pain results from a combination of joint inflammation, structural 
joint changes and pain sensitisation. In order to treat patients effectively, it is vital 
to differentiate between different types of pain, as each type should be targeted 
differently. Effective pain management approaches using a multimodal approach 
are vital to increase patient well-being, functioning and to reduce individual and 
societal costs [85].
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